These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 32160420)

  • 1. Variation in clinical and patient-reported outcomes among complex heart failure with preserved ejection fraction phenotypes.
    Flint KM; Shah SJ; Lewis EF; Kao DP
    ESC Heart Fail; 2020 Jun; 7(3):811-824. PubMed ID: 32160420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Serial Kansas City Cardiomyopathy Questionnaire Assessments With Death and Hospitalization in Patients With Heart Failure With Preserved and Reduced Ejection Fraction: A Secondary Analysis of 2 Randomized Clinical Trials.
    Pokharel Y; Khariton Y; Tang Y; Nassif ME; Chan PS; Arnold SV; Jones PG; Spertus JA
    JAMA Cardiol; 2017 Dec; 2(12):1315-1321. PubMed ID: 29094152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction: From the TOPCAT Trial.
    Anand IS; Claggett B; Liu J; Shah AM; Rector TS; Shah SJ; Desai AS; O'Meara E; Fleg JL; Pfeffer MA; Pitt B; Solomon SD
    JACC Heart Fail; 2017 Apr; 5(4):241-252. PubMed ID: 28359411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sex Differences in Outcomes and Responses to Spironolactone in Heart Failure With Preserved Ejection Fraction: A Secondary Analysis of TOPCAT Trial.
    Merrill M; Sweitzer NK; Lindenfeld J; Kao DP
    JACC Heart Fail; 2019 Mar; 7(3):228-238. PubMed ID: 30819379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial.
    Cikes M; Claggett B; Shah AM; Desai AS; Lewis EF; Shah SJ; Anand IS; O'Meara E; Rouleau JL; Sweitzer NK; Fang JC; Saksena S; Pitt B; Pfeffer MA; Solomon SD
    JACC Heart Fail; 2018 Aug; 6(8):689-697. PubMed ID: 30007557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Designing Future Clinical Trials in Heart Failure With Preserved Ejection Fraction: Lessons From TOPCAT.
    Patel RB; Shah SJ; Fonarow GC; Butler J; Vaduganathan M
    Curr Heart Fail Rep; 2017 Aug; 14(4):217-222. PubMed ID: 28647918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction: Detailed Phenotypes, Prognosis, and Response to Spironolactone.
    Cohen JB; Schrauben SJ; Zhao L; Basso MD; Cvijic ME; Li Z; Yarde M; Wang Z; Bhattacharya PT; Chirinos DA; Prenner S; Zamani P; Seiffert DA; Car BD; Gordon DA; Margulies K; Cappola T; Chirinos JA
    JACC Heart Fail; 2020 Mar; 8(3):172-184. PubMed ID: 31926856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Spironolactone on Longitudinal Changes in Health-Related Quality of Life in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial.
    Lewis EF; Kim HY; Claggett B; Spertus J; Heitner JF; Assmann SF; Kenwood CT; Solomon SD; Desai AS; Fang JC; McKinlay SA; Pitt BA; Pfeffer MA;
    Circ Heart Fail; 2016 Mar; 9(3):e001937. PubMed ID: 26962133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myocardial Infarction in Heart Failure With Preserved Ejection Fraction: Pooled Analysis of 3 Clinical Trials.
    Cunningham JW; Vaduganathan M; Claggett BL; John JE; Desai AS; Lewis EF; Zile MR; Carson P; Jhund PS; Kober L; Pitt B; Shah SJ; Swedberg K; Anand IS; Yusuf S; McMurray JJV; Pfeffer MA; Solomon SD
    JACC Heart Fail; 2020 Aug; 8(8):618-626. PubMed ID: 32387067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Machine Learning Prediction of Mortality and Hospitalization in Heart Failure With Preserved Ejection Fraction.
    Angraal S; Mortazavi BJ; Gupta A; Khera R; Ahmad T; Desai NR; Jacoby DL; Masoudi FA; Spertus JA; Krumholz HM
    JACC Heart Fail; 2020 Jan; 8(1):12-21. PubMed ID: 31606361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction.
    Solomon SD; Claggett B; Lewis EF; Desai A; Anand I; Sweitzer NK; O'Meara E; Shah SJ; McKinlay S; Fleg JL; Sopko G; Pitt B; Pfeffer MA;
    Eur Heart J; 2016 Feb; 37(5):455-62. PubMed ID: 26374849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spironolactone Use and Improved Outcomes in Patients With Heart Failure With Preserved Ejection Fraction With Resistant Hypertension.
    Tsujimoto T; Kajio H
    J Am Heart Assoc; 2020 Dec; 9(23):e018827. PubMed ID: 33222584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Visit-to-Visit Variability in Kidney Function and Serum Electrolyte Indexes With Risk of Adverse Clinical Outcomes Among Patients With Heart Failure With Preserved Ejection Fraction.
    Segar MW; Patel RB; Patel KV; Fudim M; DeVore AD; Martens P; Hedayati SS; Grodin JL; Tang WHW; Pandey A
    JAMA Cardiol; 2021 Jan; 6(1):68-77. PubMed ID: 33206129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spironolactone for Management of Heart Failure with Preserved Ejection Fraction: Whither to After TOPCAT?
    Mitter SS; Shah SJ
    Curr Atheroscler Rep; 2015 Nov; 17(11):64. PubMed ID: 26408016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Importance of Impaired Systolic Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone.
    Shah AM; Claggett B; Sweitzer NK; Shah SJ; Anand IS; Liu L; Pitt B; Pfeffer MA; Solomon SD
    Circulation; 2015 Aug; 132(5):402-14. PubMed ID: 26130119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial.
    Shah SJ; Heitner JF; Sweitzer NK; Anand IS; Kim HY; Harty B; Boineau R; Clausell N; Desai AS; Diaz R; Fleg JL; Gordeev I; Lewis EF; Markov V; O'Meara E; Kobulia B; Shaburishvili T; Solomon SD; Pitt B; Pfeffer MA; Li R
    Circ Heart Fail; 2013 Mar; 6(2):184-92. PubMed ID: 23258572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial.
    Pfeffer MA; Claggett B; Assmann SF; Boineau R; Anand IS; Clausell N; Desai AS; Diaz R; Fleg JL; Gordeev I; Heitner JF; Lewis EF; O'Meara E; Rouleau JL; Probstfield JL; Shaburishvili T; Shah SJ; Solomon SD; Sweitzer NK; McKinlay SM; Pitt B
    Circulation; 2015 Jan; 131(1):34-42. PubMed ID: 25406305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial.
    Chandra A; Vaduganathan M; Lewis EF; Claggett BL; Rizkala AR; Wang W; Lefkowitz MP; Shi VC; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; Van Veldhuisen DJ; Zannad F; Zile MR; McMurray JJV; Solomon SD;
    JACC Heart Fail; 2019 Oct; 7(10):862-874. PubMed ID: 31302043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Racial Differences in Characteristics and Outcomes of Patients With Heart Failure and Preserved Ejection Fraction in the Treatment of Preserved Cardiac Function Heart Failure Trial.
    Lewis EF; Claggett B; Shah AM; Liu J; Shah SJ; Anand I; O'Meara E; Sweitzer NK; Rouleau JL; Fang JC; Desai AS; Retta TM; Solomon SD; Heitner JF; Stamos TD; Boineau R; Pitt B; Pfeffer MA
    Circ Heart Fail; 2018 Mar; 11(3):e004457. PubMed ID: 29664406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systolic blood pressure and cardiovascular outcomes in heart failure with preserved ejection fraction: an analysis of the TOPCAT trial.
    Selvaraj S; Claggett B; Shah SJ; Anand I; Rouleau JL; Desai AS; Lewis EF; Pitt B; Sweitzer NK; Pfeffer MA; Solomon SD
    Eur J Heart Fail; 2018 Mar; 20(3):483-490. PubMed ID: 29148144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.